Group 1 - The Portnoy Law Firm is advising investors of BioAge Labs, Inc. regarding a class action related to the company's IPO on September 26, 2024, with a deadline for filing a lead plaintiff motion by March 10, 2025 [1] - BioAge announced the discontinuation of its STRIDES Phase 2 trial for azelaprag on December 6, 2024, due to safety concerns, which was unexpected given the company's previous emphasis on the product's potential during the IPO [3] - Following the announcement of the trial discontinuation, BioAge's stock price fell significantly from $20.09 per share to $4.65 per share within one day [3] Group 2 - The Portnoy Law Firm offers complimentary case evaluations for investors seeking to recover losses due to corporate wrongdoing [2][4] - The founding partner of the Portnoy Law Firm has successfully recovered over $5.5 billion for investors in similar cases [4]
BioAge Labs, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. March 10, 2025 Deadline to file Lead Plaintiff Motion.